

# Inovatyon second-line chemotherapy ovarian cancer

<b>Submission date</b> 31/10/2011	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 31/10/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 08/03/2023	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Miss Sam Ballantyne

**Contact details**  
Guy's and St Thomas' Hospital  
Great Maze Pond  
London  
United Kingdom  
SE1 9RT  
-  
samb@oclinical.com

## Additional identifiers

**EudraCT/CTIS number**  
2010-022949-17

**IRAS number**

**ClinicalTrials.gov number**  
NCT01379989

**Secondary identifying numbers**  
10836

# Study information

## Scientific Title

Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum

## Acronym

INOVATYON

## Study objectives

No data are available comparing trabectedin + PLD to a platinum-based regimen. Based on data from OVA-301 and CALYPSO the proposed INOVATYON trial will investigate the role of a non-platinum combination for the treatment of ovarian cancer patients relapsing between six and 12 months after last platinum-based chemotherapy

1. Does the combination of trabectedin and PLD prolong overall survival over carboplatin + PLD?
2. Progression Free Survival, response rate, safety profile, quality of life, Time from randomization to subsequent chemotherapy, response rate and progression free survival after subsequent therapies, overall survival counted from the administration of subsequent chemotherapy

## Sub study (Italy Only)

Pharmacokinetic analyses in plasma and ascites in a subset of patients receiving trabectedin and PLD

1. To demonstrate that the combination of trabectedin (Yondelis®) and pegylated liposomal doxorubicin (PLD) prolongs overall survival (OS) over carboplatin and PLD in patients with relapsed ovarian cancer progressing within 6-12 months after end of last platinum.
2. To evaluate the time from randomization to subsequent chemotherapy and the overall survival counted from the administration of subsequent chemotherapy.
  - 2.1. To evaluate serological response of CA-125 in each arm.
  - 2.2. To compare the quality of life (QoL) in each arm using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (QLQ-C30) and the Quality of Life Questionnaire-OV28 (QLQ-OV28).
  - 2.3. To compare safety profile, progression free survival (PFS), objective response rate (ORR), the type and length of remission (response rate and PFS) after subsequent therapies following each of the two combinations.
  - 2.4. Sub-study in selected centers (ITALY ONLY): To perform pharmacokinetic (PK) analyses in both plasma and ascites in a subset of patients receiving trabectedin and PLD

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

First MREC, 04/10/2011, ref: 11/LO/1261

## Study design

Randomised interventional treatment

## Primary study design

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

GP practice

**Study type(s)**

Treatment

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Gynaecological cancer, ovarian cancer

**Interventions**

Yondelis & PLD versus Carboplatin & PLD

Patients are either given trabectedin (Yondelis®) and pegylated liposomal doxorubicin (PLD) or carboplatin and PLD

**Intervention Type**

Drug

**Phase**

Phase III

**Drug/device/biological/vaccine name(s)**

Carboplatin, Pegylated Liposomal Doxorubicin (PLD), Trabectedin (Yondelis®)

**Primary outcome measure**

Demonstrate that the combination of trabectedin (Yondelis®) and pegylated liposomal doxorubicin

**Secondary outcome measures**

1. CA-125 response
2. To evaluate serological response of CA-125 in each arm
3. Quality of life
4. To compare the quality of life (QoL) in each arm using the European Organization for Research
5. Safety Profile
6. To compare safety profile, progression free survival (PFS), objective response rate (ORR)

Sub study (Italy only):

1. To perform pharmacokinetic (PK) analyses in both plasma
2. Time to subsequent chemotherapy
3. To evaluate the time from randomization to subsequent chemotherapy and the overall survival counted

**Overall study start date**

01/05/2011

**Completion date**

01/12/2013

## **Eligibility**

**Key inclusion criteria**

1. Female, aged = 18 years
2. Histologically and/or cytologically proven epithelial ovarian, epithelial fallopian tube cancer or primary peritoneal cancer
3. Progression-free interval between six and twelve (6-12) months (calculated from the first day of the last cycle of the last platinum-based chemotherapy until the date of progression confirmation through radiologic imagery). Patients may have received up to two platinum-based chemotherapy lines, of which at least one must have contained a taxane
4. Measurable or evaluable disease confirmed by radiological imaging, such as magnetic resonance imaging (MRI), computed tomography (CT) scan, or PET/CT scan at study entry. CA-125 rise not supported by radiological evidence of disease is not accepted as criteria for defining progression) or histological proven recurrent ovarian cancer even in the absence of postoperatively measurable or evaluable lesions
5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 2
6. Estimated life expectancy = 12 weeks
7. Patients must be accessible for treatment and follow-up
8. Adequate organ function within 14 days prior to first cycle as evidenced by:
  - 8.1. Peripheral blood counts and serum chemistry values:
    - 8.1.1. Hemoglobin  $\geq 9$  g/dl
    - 8.1.2. Absolute neutrophil count (ANC)  $\geq 1,500/\text{ml}$
    - 8.1.3. Platelet count  $\geq 100,000/\text{ml}$
    - 8.1.4. Estimated glomerular filtration rate  $> 60$  ml/min according to the Cockcroft-Gault formula
    - 8.1.5. Creatine phosphokinase (CPK) =  $2.5 \times \text{ULN}$
  - 8.2. Hepatic function variables:
    - 8.2.1. Total bilirubin  $\leq \text{ULN}$
    - 8.2.2. Total alkaline phosphatase  $2.5 \times \text{ULN}$  (consider hepatic isoenzymes 5-nucleotidase if the elevation could be osseous in origin)
    - 8.2.3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be  $\leq 2.5 \times \text{ULN}$
9. Patients must be able to receive dexamethasone or its equivalent, which is required if randomly assigned to treatment with trabectedin plus PLD
10. Informed consent of the patient

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Female

## **Target number of participants**

Planned Sample Size: 588. 442 events and about 588 patients are needed

## **Total final enrolment**

617

## **Key exclusion criteria**

1. Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g., Mullerian tumors)
2. Patients who did not respond to last platinum-based therapy or in whom last relapse occurred < 6 months or > 12 months from the last dose of platinum
3. Bowel obstruction, sub-occlusive disease or the presence of symptomatic brain metastases
4. Pre-existing grade > 1 motor or sensory neuropathy according to the National Cancer Institute Common Toxicity Criteria Adverse Event (NCI-CTCAE) version 4.0
5. Myocardial infarct within six months before enrolment, New York Heart Association (NYHA) Class II or worse heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities
6. History of liver disease
7. Concurrent severe medical problems or any unstable medical condition unrelated to malignancy, which would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy
8. Breastfeeding women and women of child bearing potential must use effective contraception during treatment and 3 months thereafter, which may include prescription contraceptives (oral, injection, or patch), intrauterine device, double-barrier method or male partner sterilization (not applicable to patients that are surgically sterile)
9. Prior exposure to trabectedin
10. Prior resistance to anthracyclines or PLD defined as a progression during anthracycline-based chemotherapy or a recurrence within 6 months from its ending
11. Prior severe PLD related toxicity
12. Prior exposure to cumulative doses of doxorubicin >400mg/m<sup>2</sup> or epirubicin >720mg/m<sup>2</sup>
13. Treatment with any investigational product within 30 days prior to inclusion in the study
14. Patients with known hypersensitivity to Trabectedin and any of its excipients or yellow fever vaccine
15. Patients with concurrent serious or uncontrolled infection
16. Patients in need of yellow fever vaccine while on study chemotherapy

## **Date of first enrolment**

01/05/2011

## **Date of final enrolment**

01/12/2013

## **Locations**

### **Countries of recruitment**

Denmark

England

Finland

Germany

Italy

Spain

United Kingdom

**Study participating centre**

**Guy's and St Thomas' Hospital**

London

United Kingdom

SE1 9RT

## **Sponsor information**

**Organisation**

Mario Negri Gynecological Oncology Group - MaNGO (Italy)

**Sponsor details**

[Istituto di Ricerche Farmacologiche "Mario Negri"]

Via La Masa

Milano

Italy

19 - 20156

**Sponsor type**

Research organisation

**Website**

<http://www.marionegri.it/mn/en/index.html>

**ROR**

<https://ror.org/01qd3xc93>

## **Funder(s)**

**Funder type**

Industry

**Funder Name**

Pharma Mar (Spain)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available later

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Plain English results</a>	outcome results	16/07/2021	20/07/2021	No	Yes
<a href="#">Results article</a>		09/02/2023	08/03/2023	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No